

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (Original) A medical device comprising:  
an implantable structure;  
a basecoat matrix, including a combination of rapamycin and a topoisomerase I inhibitor, in therapeutic dosages, incorporated in a first polymeric material, the basecoat matrix being affixed to the surface of the implantable medical device; and  
a topcoat, including a second polymeric material, affixed to the basecoat matrix for controlling the elution rate of the rapamycin and the topoisomerase I inhibitor.
2. (Original) The medical device according to claim 1, wherein the topoisomerase I inhibitor comprises topotecan.
3. (Original) The medical device according to claim 1, wherein the topoisomerase I inhibitor comprises irinotecan.
4. (Original) The medical device according to claim 1, wherein the topoisomerase I inhibitor comprises camptothecin.
5. (Original) The medical device according to claim 1, wherein the topoisomerase I inhibitor comprises DX-8951f.
6. (Original) The medical device according to claim 1, wherein the implantable structure comprises a stent.

7. (Original) The medical device according to claim 1, wherein the implantable structure comprises a stent-graft.
8. (Original) The medical device according to claim 1, wherein the implantable structure comprises an anastomosis device.
9. (Previously Presented) The medical device according to claim 1, wherein the second polymeric material is incompatible with the first polymeric material, thereby creating both a physical and chemical barrier to the elution of the rapamycin and topoisomerase I inhibitor eladribine.
10. (Original) The medical device according to claim 9, wherein the first polymeric material comprises a fluoropolymer.
11. (Original) The medical device according to claim 9, wherein the second polymeric material comprises an acrylic.
12. (Cancelled) A medical device comprising:  
an implantable structure; and  
a combination of rapamycin and a topoisomerase I inhibitor, in therapeutic dosages, releasably affixed to the implantable structure for the treatment of restenosis following vascular injury.
13. (Cancelled) The medical device according to claim 12, wherein the topoisomerase I inhibitor comprises topotecan.
14. (Cancelled) The medical device according to claim 12, wherein the topoisomerase I inhibitor comprises irinotecan.

15. (Cancelled) The medical device according to claim 12, wherein the topoisomerase I inhibitor comprises camptothecin.
16. (Cancelled) The medical device according to claim 12, wherein the topoisomerase I inhibitor comprises DX-8951f.
17. (Cancelled) The medical device according to claim 12, wherein the implantable structure comprises a stent.
18. (Cancelled) The medical device according to claim 12, wherein the implantable structure comprises a stent-graft.
19. (Cancelled) The medical device according to claim 12, wherein the implantable structure comprises an anastomosis device
20. (Cancelled) The medical device according to claim 12, further comprising a polymeric coating, the combination of rapamycin and cladribine being incorporated into the polymeric coating.
21. (Cancelled) A method for treating restenosis comprising the local administration of a therapeutic dose of a combination of rapamycin and a topoisomerase I inhibitor.
22. (Cancelled) A method for treating restenosis comprising the administration of a therapeutic dose of a combination of rapamycin and topotecan.
23. (Cancelled) A medical device comprising:  
an implantable medical structure; and  
a combination of rapamycin and topotecan, in therapeutic

dosages, releasably affixed to the implantable structure for the treatment of restenosis following vascular injury.

24. (Cancelled) A medical device comprising:  
an implantable structure; and  
a topoisomerase I inhibitor, in therapeutic dosages, releasably affixed to the implantable structure for the treatment of restenosis following vascular injury.